Public consultation on proposed amendments to the Poisons Standard - ACMS/ACCS/Joint ACMS-ACCS, NOVEMBER 2022

Closed 29 Sep 2022

Opened 1 Sep 2022

Contact

Medicines Scheduling

1800 020 653

medicines.scheduling@health.gov.au

Feedback updated 3 Feb 2023

We asked

Between 1 September 2022 to 29 September 2022, we sought submissions from the public on scheduling proposals referred to the November 2022 meetings of the Advisory Committees on Medicines and Chemicals Scheduling. Respondents were given the choice to indicate their support or opposition to the proposed amendments using survey buttons, with or without a written response.

You said

A total of 30 responses were received through the consultation. A breakdown of the submissions can be found below.

Ivermectin: 17 responses were received — 12 supportive of the proposed amendment and 5 opposed. All contained a written component.

Brimonidine: 3 responses were received, all of which were supportive of the proposed amendments but did not contain a written component.

Fexofenadine: 2 responses were received — one (1) supportive of the proposed amendment and one (1) opposed. Both submissions contained written responses.

Ibuprofen: 5 responses were received, all with a written component — one (1) supportive of the proposed amendment and 4 opposed.

Melatonin: 5 responses were received, all with a written component — 4 supportive of the proposed amendment and one (1) opposed.

Green tea extract: 7 responses were received, all with a written component — one (1) supportive, 3 partially supportive and 4 opposed to the proposed amendments.

Ethalfluralin: One (1) written submission was received that was supportive of the proposed amendment.

Tigolaner: No responses were received regarding the proposed amendment.

We did

The Delegate considered all submissions prior to making their interim decisions on these substances. The interim decisions were published on 3 February 2023. Following another round of public consultation final decisions for these substances will be published in April 2023.

Published responses

View submitted responses where consent has been given to publish the response.

Overview

Scheduling amendments referred to expert advisory committee

Please note that this consultation does not include public submissions for paracetamol. To visit the consultation for paracetamol, please see the below link:

This consultation is for applications and delegate-initiated proposals to amend the Poisons Standard. The scheduling amendments and any submissions received will be considered at the November 2022 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).

The closing date for this consultation is close of business 29 September 2022. All submissions received by the deadline will be considered by the delegate before they make an interim decision.

The proposals under consultation are detailed in the public notice of November 2022.

Substances for which public comment is sought in this consultation:

  • Ivermectin
  • Brimonidine
  • Fexofenadine
  • Ibuprofen
  • Melatonin 
  • Green tea extract
  • Ethalfluralin
  • Tigolaner

What happens next

All public submissions will be published on the TGA website at Public submissions on scheduling matters, unless marked confidential or indicated otherwise in the submission information (see Privacy and your Personal information).

Public submissions are an important part of the process for amending the Poison Standard, and are published on the TGA website using the consultation hub.  Submissions by the public may not reflect the views of the Department of Health or TGA.  Published submissions should not be taken as being endorsed by the Department or TGA.

Following consideration of public submissions received before the closing date and advice from the expert advisory committee/s, decisions on the proposed amendments are anticipated to be published as interim decisions on the TGA website: Scheduling delegate's interim decisions & invitations for further comment in February 2023.

Audiences

  • Aboriginal and Torres Strait Islander People
  • Seniors
  • Men
  • Women
  • Carers and guardians
  • Families
  • Parents
  • Young people
  • Academics
  • Non-government organisations
  • State government agencies
  • Commonwealth agencies
  • Local governments
  • Health professionals
  • Health workforce
  • General public
  • Community groups
  • Businesses
  • Contracted Service Providers
  • Aged care service providers
  • Aged care workforce
  • Aged care professionals
  • BPRU staff
  • Graduates
  • Online and Publications staff
  • Secretariat
  • PCCD
  • Health staff
  • HPRG (TGA) Staff
  • Prescription medicines
  • Complementary medicines
  • Over-the-counter medicines
  • Medical Devices & IVDs
  • Biologicals
  • Other

Interests

  • Policy Development